The FDA approved the enVista Envy full range of vision IOL from Bausch + Lomb, according to a press release.
In a multicenter, randomized, controlled clinical trial of 332 participants, the IOL demonstrated “excellent long-term outcomes,” the release said, with 86% of patients reporting little to no issues with dysphotopsia. In addition, a clinical study performed in Canada with 110 participants found that 94% of patients reported little to no difficulty viewing close objects, and 93% were “completely to moderately satisfied” with their vision after surgery.
The enVista